Events by this organizer

Details: Clinical audit | RACGP: 40 points | ACRRM: 7 hours | GPs only

Overview: By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. Timely diagnosis and appropriate pharmacological management are essential to reduce osteoporotic fracture rates. However, fractures are often not linked to osteoporosis, or are seen as unimportant. The disease therefore remains underdiagnosed and undertreated in Australian General Practice.

This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Details: Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only

Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

Details: Clinical audit | RACGP: 40 points | ACRRM: 7 hours | GPs only

Overview: By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. Timely diagnosis and appropriate pharmacological management are essential to reduce osteoporotic fracture rates. However, fractures are often not linked to osteoporosis, or are seen as unimportant. The disease therefore remains underdiagnosed and undertreated in Australian General Practice.

This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Details: Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only

Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

Details: Clinical audit | RACGP: 40 points | ACRRM: 7 hours | GPs only

Overview: By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. Timely diagnosis and appropriate pharmacological management are essential to reduce osteoporotic fracture rates. However, fractures are often not linked to osteoporosis, or are seen as unimportant. The disease therefore remains underdiagnosed and undertreated in Australian General Practice.

This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Details: Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only

Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

Details: Clinical audit | RACGP: 40 points | ACRRM: 7 hours | GPs only

Overview: By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. Timely diagnosis and appropriate pharmacological management are essential to reduce osteoporotic fracture rates. However, fractures are often not linked to osteoporosis, or are seen as unimportant. The disease therefore remains underdiagnosed and undertreated in Australian General Practice.

This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Details: Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only

Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

Details: Clinical audit | RACGP: 40 points | ACRRM: 7 hours | GPs only

Overview: By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. Timely diagnosis and appropriate pharmacological management are essential to reduce osteoporotic fracture rates. However, fractures are often not linked to osteoporosis, or are seen as unimportant. The disease therefore remains underdiagnosed and undertreated in Australian General Practice.

This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Details: Clinical audit | RACGP: 40 points | ACRRM: 6 hours | GPs only

Overview: Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.